SELLAS Life Sciences Group financials
$11.51−0.69%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $1.0M | $7.6M | $1.9M | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $900.0K | $7.4M | $1.9M | $0.00 | — |
| Gross margin | — | — | — | 90.0% | 97.4% | 100.0% | — | — |
| Operating income | -$28.3M | -$31.5M | -$37.9M | -$42.0M | -$25.3M | -$17.0M | -$20.0M | -$31.1M |
| Net income | -$26.9M | -$30.9M | -$37.3M | -$41.3M | -$20.7M | -$16.8M | -$28.0M | -$41.3M |
| Net margin | — | — | — | −4130.1% | −272.4% | −886.1% | — | — |
| Diluted EPS | $-0.25 | $-0.50 | $-1.34 | $-2.13 | $-1.34 | $-2.11 | $-10.92 | $-157.72 |
| EBITDA | -$28.3M | -$31.5M | -$37.9M | -$31.9M | -$19.6M | -$17.0M | -$17.2M | -$21.5M |
| Operating cash flow | -$28.4M | -$35.4M | -$31.4M | -$28.3M | -$26.0M | -$10.4M | -$17.6M | -$30.4M |
| Free cash flow | -$28.4M | -$35.4M | -$31.4M | -$28.3M | — | — | — | — |
| Diluted shares | 109.1M | 61.2M | 27.8M | 19.4M | 15.5M | 8.0M | 2.6M | 0.3M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $71.8M | $13.9M | $2.5M | $17.1M | $21.4M | $35.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $78.3M | $19.4M | $6.2M | $20.9M | $26.3M | $46.0M |
| Total liabilities | $7.5M | $10.0M | $14.2M | $16.1M | $5.9M | $18.1M |
| Shareholders' equity | $70.9M | $9.5M | -$8.0M | $4.9M | $20.3M | $28.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology